Liraglutide Use in Prader-Willi Syndrome

Status Terminated

Clinical Trial Summary

Liraglutide is a glucagon like peptide -1 (GLP-1) agonist, which is approved for use in patients with type 2 diabetes. Studies of liraglutide have shown an appetite suppressive effect and has been associated with weight loss in patients with type 2 diabetes. Liraglutide use in the treatment of PWS is limited to one case report by Cyganek et el (See attached Citation). In this case report, the subject showed improvements in hemoglobin A1c and body weight over 14 weeks.

The investigators plan to examine the use of liraglutide in a single subject with Prader Willi Syndrome and type 2 diabetes for one year. The investigators will examine clinical parameters, clinical assessment of hunger, and biochemical markers of diabetes and lipid control.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01542242
Study type	Interventional
Source	Vancouver General Hospital
Contact
Status	Terminated
Phase	Phase 4
Start date	February 2012
Completion date	March 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01267448` - Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia	Phase 4
Active, not recruiting	`NCT05330247` - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study	N/A
Terminated	`NCT02743598` - Liraglutide for HIV-associated Neurocognitive Disorder	Phase 4
Terminated	`NCT02373865` - Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes	Phase 4
Completed	`NCT01741181` - Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2	Phase 4
Completed	`NCT01305434` - Mulberry Leaf Extract and Blood Glucose Control in Diabetics	Phase 1/Phase 2
Completed	`NCT01330121` - Bridging the Gap by Transitional Care	N/A
Recruiting	`NCT00992797` - Diabetes Intervention Trial With Vitamin D in Subjects of Nordic and Sub-Indian Ethnicity	Phase 2
Completed	`NCT01580904` - Impact of Pharmaceutical Care in Diabetics Patients	N/A
Active, not recruiting	`NCT00728403` - Metabolic and Therapeutic Effects of American and Korean Red Ginseng in the Treatment of Type 2 Diabetes	Phase 2
Completed	`NCT00763815` - GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone	Phase 3
Active, not recruiting	`NCT00529815` - Continuous Glucose Monitoring in Patients With Type 2 Diabetes	Phase 4
Completed	`NCT00517465` - A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.	Phase 1
Completed	`NCT00119041` - Diabetes Telemedicine Consultation: A Systems Improvement Intervention	N/A
Withdrawn	`NCT00417716` - Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema	Phase 3
Withdrawn	`NCT00600236` - HLA and it Relation With the Development of Proliferative Diabetic Retinopathy in Mexican Population	Phase 3
Active, not recruiting	`NCT05887635` - Study of Duodenal Mucosal RF Vapor Ablation in Subjects With Type-2 Diabetes Mellitus	N/A
Completed	`NCT03903965` - Comparison of Retinal Perfusion Between Diabetic and Non-diabetic Patients With OCT Angiography After Cataract Surgery.
Completed	`NCT02666924` - Cooking Classes for Chinese Canadian Patients Living With Diabetes	N/A
Recruiting	`NCT02501850` - The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)	Phase 4